Replimune schedules Type A meeting with FDA to discuss RP1 CRL; program viability at risk

Replimune Group, Inc.

FDA Type A meeting scheduled to discuss CRL for RP1 BLA in advanced melanoma; briefing submitted with additional analysis.
CEO states without accelerated approval, RP1 program in advanced melanoma, including phase 3 confirmatory trial, will not be viable.
Stockholders voted against amending 2018 Omnibus Incentive Compensation Plan (26.97M for, 35.49M against).
All director nominees elected; PwC ratification and say-on-pay proposals approved by stockholders.

item 5.07item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.